Arlindo R. Ferreira

Invited Assistant Professor

Generic Bio

Participation in Católica Medical School

  • Curricular Unit Growth and Development I

 

Field of Work 

  • Breast Cancer - Clinical Practice of Medical Oncology and Clinical Research 

 

Profissional Activity

  • Champalimaud Foundation, Medical Oncologist and Clinical Researcher 
  • Universidade Católica Portuguesa, Católica Medical School 

 

Education

  • Nov. 2015 – Oct. 2020: PhD in Medicine, branch Oncology at University of Lisbon, Faculdade de Medicina, Instituto de Medicina Molecular; Lisbon, Portugal 
  • Sep. 2012 – Jun. 2015: Master Degree in Clinical Research and Regulatory Affairs for Drugs, Biologics, and Medical Devices at Nova University of Lisbon, Lisbon, Portugal and Northeastern University, Boston, USA 
  • Feb. 2015 – Jun 2015: CORe: Credential of Readiness at HBX | Harvard Business School, Boston, USA 
  • Mar. 2012 – Dec. 2014: Clinical Scholars Research Training I and II at HMS | Harvard Medical School - Portugal Program, Boston, USA 
  • Sep. 2004 – Jul. 2010: Degree in Medicine at University of Lisbon, Lisbon, Portugal; Final score 17.1 out of 20. 

 

Summary of Professional Career

  • Mar. 2019 – present: Medical Oncologist and Clinical Researcher in Champalimaud Foundation, Champalimaud Clinical Center, Breast Unit 
  • Sep. 2021 – present: Invited Assistant Professor at Universidade Católica Portuguesa, Católica Medical School  
  • Nov. 2018 – Feb. 2019: Clinical Research Fellow at Gustave Roussy – Cancer Campus, Villejuif, France (Clinical research in breast cancer)
  • Jan. 2012 – Nov. 2018: Medical Oncology Resident at Centro Hospitalar Lisboa Norte, Lisbon, Portugal (Clinical practice in medical oncology. Multidisciplinary clinical research with collaboration in industry initiated clinical trials and investigator initiated observational studies.)
  • May. 2017 – Jul. 2017: Clinical Research Fellow at Institut Jules Bordet, Brussels, Belgium (Clinical research in breast cancer.)
  • Jul. 2014 – Sep. 2015: Clinical Research Fellow at Dana Farber Cancer Institute, Boston, USA (Clinical research in breast cancer. Focus on the prognostic and predictive features of hormone receptor positive breast cancer and clinical trial design.)
  • Jan. to Dec. 2011: General residency (Foundation year) at Centro Hospitalar Lisboa Central, Lisbon, Portugal (Foundation year of medical practice – Rotations in Internal Medicine, Medical Oncology, General Surgery, Pediatrics, Obstetrics & Gynecology, Family Medicine and Public Health Medicine.)


Languages

Portuguese | English

 

Other Interests

  • Clinical research
  • Clinical trials
  • Outcomes research
  • Comparative effectiveness
  • Quality of life 

 

Paper

Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Arlindo R. Ferreira (with Mariana Brandão). 2024. Breast Cancer Research and Treatment
Paper

Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium

Arlindo R. Ferreira (with Mariana Brandão). 2024. Breast Cancer Research and Treatment
Paper

ESMO Expert Consensus Statements on Cancer Survivorship: promoting high-quality survivorship care and research in Europe

Arlindo R. Ferreira (with Vaz-Luis, I.). 2022. Annals of Oncology
Other

Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast Cancer

Arlindo R. Ferreira (with Zañudo, J.G.T.). 2022. medRxiv
Paper

Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study

Arlindo R. Ferreira (with Cardoso Borges, F.). 2022. Breast
Paper

Targeted Axillary Dissection after Chemotherapy: Feasibility Study with Clip and Carbon Dye Tattoo - Neotarget Trial

Arlindo R. Ferreira (with Pinto, D.). 2022. Breast Care
Paper

Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial

Arlindo R. Ferreira (with Arlindo R. Ferreira). 2021. European Journal of Cancer
Paper

Breast cancer surgery with augmented reality

Arlindo R. Ferreira (with Pedro F. Gouveia). 2021. The Breast
Paper

Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants

Arlindo R. Ferreira (with Lambertini, M.). 2021. npj Breast Cancer
Paper

Safety of assisted reproductive techniques in young women harboring germline pathogenic variants in BRCA1/2 with a pregnancy after prior history of breast cancer

Arlindo R. Ferreira (with Condorelli, M.). 2021. ESMO Open
Paper

Use of mHealth to Increase Physical Activity Among Breast Cancer Survivors With Fatigue: Qualitative Exploration

Arlindo R. Ferreira (with Elise Martin). 2021. JMIR Cancer
Paper

Body weight and return to work among survivors of early-stage breast cancer

Arlindo R. Ferreira (with Di Meglio, A.). 2020. ESMO Open
Paper

Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical study

Arlindo R. Ferreira (with Di Meglio, A.). 2020. Breast
Paper

Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study

Arlindo R. Ferreira (with Blondeaux, E.). 2020. ESMO Open
Paper

Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis

Arlindo R. Ferreira (with Mariana Brandão). 2020. ESMO Open
Paper

Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases

Arlindo R. Ferreira (with Soraia Lobo-Martins). 2020. Cancers
Paper

Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk

Arlindo R. Ferreira (with Pistilli, B.). 2020. Journal of Clinical Oncology
Other

Use of mHealth to Increase Physical Activity Among Breast Cancer Survivors With Fatigue: Qualitative Exploration (Preprint)

Arlindo R. Ferreira (with Elise Martin). 2020.
Paper

Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis

Arlindo R. Ferreira (with A.R. Ferreira). 2019. Annals of Oncology
Paper

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.

Arlindo R. Ferreira (with Lambertini M). 2019. Breast cancer research and treatment
Paper

Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study

Arlindo R. Ferreira (with Ferreira, A.R.). 2019. Clinical Breast Cancer
Paper

Levels of circulating fibroblast growth factor 23 (FGF23) and prognosis in cancer patients with bone metastases

Arlindo R. Ferreira (with Mansinho, A.). 2019. International Journal of Molecular Sciences
Paper

Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade

Arlindo R. Ferreira (with Otto Metzger‐Filho). 2019. The Oncologist
Paper

Modelling cancer outcomes of bone metastatic patients: Combining survival data with N-Telopeptide of type i collagen (NTX) dynamics through joint models 01 Mathematical Sciences 0104 Statistics

Arlindo R. Ferreira (with Loureiro, H.). 2019. BMC Medical Informatics and Decision Making
Paper

Chemoradiotherapy completion and neutropenia risk in HIV patients with cervical cancer

Arlindo R. Ferreira (with Vendrell, I.). 2018. Medicine (United States)
Paper

Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer

Arlindo R. Ferreira (with Maurer, C.). 2018. Breast
Paper

Neoadjuvant treatment of stage IIB/III triple negative breast cancer with cyclophosphamide, doxorubicin, and Cisplatin (CAP Regimen): A single arm, single center Phase II study (GBECAM 2008/02)

Arlindo R. Ferreira (with Ferreira, A.R.). 2018. Frontiers in Oncology
Paper

Adjuvant zoledronic acid to treat breast cancer: not for all

Arlindo R. Ferreira (with Costa, L.). 2017. The Lancet Oncology
Paper

Bone metastasis risk factors in breast cancer.

Arlindo R. Ferreira (with Pulido C). 2017.
Paper

Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.

Arlindo R. Ferreira 2017. Breast (Edinburgh, Scotland)
Paper

Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study

Arlindo R. Ferreira (with Lambertini, M.). 2017. Clinical Breast Cancer
Paper

Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients.

Arlindo R. Ferreira 2017. Annals of oncology : official journal of the European Society for Medical Oncology
Paper

Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.

Arlindo R. Ferreira 2017. Cancer treatment reviews
Paper

Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases.

Arlindo R. Ferreira (with Ferreira AR). 2017.
Paper

Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study.

Arlindo R. Ferreira 2017. Breast (Edinburgh, Scotland)
Paper

Dynamic modeling of bone metastasis, microenvironment and therapy

Arlindo R. Ferreira (with Rui Moura Coelho). 2016. Journal of Theoretical Biology
Paper

Hypocalcemia in patients with metastatic bone disease treated with denosumab

Arlindo R. Ferreira (with André Mansinho). 2016. Ann. Joint
Paper

Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?

Arlindo R. Ferreira 2016. International Journal of Molecular Sciences
Paper

N-telopeptide of type I collagen long-term dynamics in breast cancer patients with bone metastases: Clinical outcomes and influence of extraskeletal metastases

Arlindo R. Ferreira (with Ferreira, A.R.). 2016. Oncologist
Paper

The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases

Arlindo R. Ferreira (with Arlindo Ferreira). 2016. Oncotarget
Paper

Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional Portuguese cohort study

Arlindo R. Ferreira (with Arlindo R. Ferreira). 2016. The Breast
Other

Bone Metastases

Arlindo R. Ferreira (with Arlindo R. Ferreira). 2015. International Manual of Oncology Practice
Paper

Bone remodeling markers and bone metastases: From cancer research to clinical implications

Arlindo R. Ferreira (with Arlindo Ferreira). 2015. BoneKEy Rep
Paper

Nocturnal blood pressure dipping in acute ischemic stroke

Arlindo R. Ferreira (with Sargento-Freitas, J.). 2015. Acta Neurologica Scandinavica
Paper

Patterns of care and clinical outcomes of first-line trastuzumab-based therapy in HER2-positive metastatic breast cancer patients relapsing after (Neo)adjuvant trastuzumab: An Italian multicenter retrospective cohort study

Arlindo R. Ferreira (with Lambertini, M.). 2015. Oncologist
Paper

Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors

Arlindo R. Ferreira (with Matteo Lambertini). 2015. Expert Opinion on Biological Therapy
Other

Prostate Cancer

Arlindo R. Ferreira (with Arlindo R. Ferreira). 2015. International Manual of Oncology Practice
Paper

Treatment of early-stage HER2 breast cancer—an evolving field

Arlindo R. Ferreira (with Arlindo R Ferreira). 2015. ecancer